28-7 focuses on researching and developing of non-coding RNA module for the treatment of cancer diseases... Read more
28-7 focuses on researching and developing of non-coding RNA module for the treatment of cancer diseases... Read more
News
Nov 02, 2022
Markets Insider
Twentyeight-Seven Therapeutics: Basilea Pharma To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-SevenTherapeutics
Jan 28, 2020
Biomass Magazine
Twentyeight-Seven Therapeutics: Seven companies join American Biogas Council board
May 09, 2019
PE Hub Network
Twentyeight-Seven: Twentyeight-Seven Therapeutics nabs $15 mln
Sep 07, 2018
PharmaLive
Twentyeight-Seven: 28-7 Therapeutics Raises $65 Million to Advance Tumor Suppressor Research
Sep 07, 2018
FierceBiotech
Twentyeight-Seven: Twentyeight-Seven Therapeutics brought on Shomir Ghosh, Ph.D., to be its CSO. Ghosh most recently served as CSO and founding scientist at IFM Therapeutics after serving as VP of drug discovery at GSK's short-lived immunology spinout Tempero Pharmaceuticals
Sep 06, 2018
FierceBiotech
Twentyeight-Seven Therapeutics: 28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNA
Sep 06, 2018
BioCentury
Twentyeight-Seven: Non-coding RNA company Twentyeight-Seven debuts with $65M
Twentyeight-Seven Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10